Business
Mesoblast sees lasting need for COVID treatment beyond a vaccine – Sydney Morning Herald
The next two months will be hugely important for the stem cell therapy company’s research projects, and its growth prospects as it works on a product to treat the deadly disease.
Mesoblast is hoping its flagship product remestemcel-L will be shown to relieve acute respiratory distress syndrome (ARDS) in COVID-19 patients. The company is running a phase 3 trial of the product in US hospitals, but the research is still in its early stages, with a pilot study of the project looking at only 12 patients.
The US Data Safety Monitoring board, which reviews clinical data, had selected a date in early September to complete an initial review of Mesoblast’s phase 3 trial, the comp…
-
General23 hours agoOf saints and sinners | The Spectator Australia
-
General23 hours agoWhy the nation needs the Nationals to ditch Net Zero
-
General23 hours agoChina and Philippines trade blame over latest South China Sea clash
-
General23 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire